慢性淋巴细胞白血病患者二线治疗的真实世界结局
该研究基于丹麦全国CLL登记与病历资料,回顾性纳入286例接受二线治疗的慢性淋巴细胞白血病(CLL)患者,比较靶向药物与化疗免疫治疗的生存和不良事件。靶向治疗组3年无治疗生存率和总生存率估计值均高于FCR/BR和CD20Clb/Clb组;靶向治疗组92%发生不良事件,其中53%为严重不良事件。
要点
- 靶向二线治疗3年无治疗生存率63%(95%CI 50%-76%),高于FCR/BR的37%和CD20Clb/Clb的22%。
- 靶向二线治疗3年总生存率估计值79%(95%CI 68%-91%),高于FCR/BR的70%和CD20Clb/Clb的60%。
- 靶向治疗组92%发生不良事件,其中53%为严重不良事件;最常见为感染和血液学不良事件。
核心结论
- 真实世界数据显示,CLL二线靶向治疗的3年无治疗生存率高于化疗免疫治疗,总生存率有升高趋势,在可能更衰弱、合并症更多的患者中亦然。
研究设计与样本
- 丹麦全国人群队列回顾性研究,数据来自病历和丹麦国家CLL登记,纳入286例接受二线治疗的CLL患者。
主要发现
- 靶向治疗(伊布替尼/维奈克拉/艾德拉尼)3年无治疗生存率为63%(95%CI 50%-76%),FCR/BR为37%(95%CI 26%-48%),CD20Clb/Clb为22%(95%CI 10%-33%)。
- 靶向治疗3年总生存率估计值为79%(95%CI 68%-91%),FCR/BR为70%(95%CI 60%-81%),CD20Clb/Clb为60%(95%CI 47%-74%)。
- 靶向治疗组92%发生不良事件,其中53%为严重不良事件;FCR/BR组和CD20Clb/Clb组分别75%和53%发生不良事件,其中63%和31%为严重不良事件。
- 最常见的不良事件为感染和血液学不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For chronic lymphocytic leukaemia (CLL), targeted drugs have become the standard of care, in particular for second-line treatment. In this study, overall survival (OS), treatment-free survival (TFS) and adverse events (AE) were registered retrospectively in a Danish population-based cohort upon second-line treatment for CLL. Data were collected from medical records and the Danish National CLL register. For 286 patients receiving second-line treatment, three-year TFS was higher upon targeted treatment (ibrutinib/venetoclax/idelalisib) [63%, 95% confidence interval (CI) 50%-76%] compared with fludarabine, cyclophosphamide and rituximab or bendamustine and rituximab (FCR/BR) (37%, CI: 26%-48%) and chlorambucil+/-CD20-antibody (CD20Clb/Clb) (22%, CI: 10%-33%). Upon targeted treatment, three-year OS estimates were higher for targeted treatment (79%, CI: 68%-91%) compared with FCR/BR (70%, CI: 60%-81%) or CD20Clb/Clb (60%, CI: 47%-74%). The most common AEs were infections and haematological AEs; 92% of patients treated with targeted drugs had AEs, 53% of which were severe. Upon FCR/BR and CD20Clb/Clb, AEs were present for 75% and 53% respectively, of which 63% and 31% were severe. These real-world data demonstrate higher TFS and a tendency towards higher OS following targeted second-line treatment for CLL compared to chemoimmunotherapy, also for patients who may be frailer and more comorbid.
引用
- Vainer N, Aarup K, Andersen MA, et al. Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia. Br J Haematol. 2023. PMID: 36896699. doi:10.1111/bjh.18715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。